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ABSTRACT
For patients with colorectal liver metastases, hepatic resection is the
treatment of choice, and the 5-year survival rate following surgery now
exceeds 50%. Timely multidisciplinary and multimodality approaches
that may include preoperative systemic chemotherapy, preoperative
portal vein embolization, extended hepatic resection, and two-stage
hepatectomy, have enabled a large proportion of patients to undergo
potentially curative treatment. The definition of resectability has shifted
from a focus on tumor characteristics, such as tumor number and size, to
determination of whether both intrahepatic and extrahepatic disease
can be completely resected and whether such an approach is appro-
priate from an oncologic standpoint for a given patient. Future
identification of molecular factors may aid in predicting prognosis of
patients with colorectal liver metastases and in improving the selection
of patients most likely to benefit from surgery. Hepatobiliary surgeons
and medical oncologists should work together to individualize  treat-
ment strategies to maximize long-term survival in patients with
colorectal liver metastases.
Gastrointest Cancer Res 1:20–27. © 2007 by International Society of Gastrointestinal Oncology
Colorectal cancer is the second leadingcause of cancer-related mortality
worldwide. Every year in the United States,
more than 140,000 patients are diagnosed
and 56,000 die of this disease.1 Although
85% of patients with colorectal carcinoma
have tumors amenable to curative resec-
tion at the time of diagnosis, the disease
recurs in more than half of patients within
5 years. The most frequent sites of colo-
rectal cancer metastases are the liver (in
30% to 60% of cases), and the lung (in
20% to 30% of the cases). Up to 25% of
colorectal cancer patients are found to
have liver metastases at presentation, and
a further 30% develop liver metastases at
a later point in the disease course, usually
within the first 2 years following primary
tumor resection.2
Without treatment, median survival of
patients with colorectal liver metastases (CLM)
is 12 to 15 months, and 5-year survival is
less than 5%. Rather disappointingly, despite
the introduction of a wide range of new
agents, median survival for patients with
stage IV disease treated with the best avail-
able chemotherapy remains only 25
months.3,4 Although many different treat-
ment modalities have been investigated, at
present, liver resection remains the best
option for achieving long-term survival. Not
all authors agree that aggressive surgery
for CLM is appropriate; some argue that the
benefit in terms of survival after this proce-
dure could be the result of better patient
selection rather than of the treatment
strategy. Although tumor biology is likely to
prevail regardless of treatment, the natural
history of stage IV colon cancer is clearly
altered in many patients who undergo
complete hepatic resection of CLM. Thus,
integrated therapy with surgery and systemic
chemotherapy is of increased importance.
Thanks to advances in multimodality treat-
ment, many patients with CLM who would
have been considered unresectable just a few
years ago are today candidates for resec-
tion. The current 5-year overall survival rate
after surgery has reached a new bench-
mark of 58%.5–10
ASSESSMENT OF HEPATIC
INVOLVEMENT 
A systematic and careful preoperative assess-
ment of hepatic involvement is mandatory
for  accurate selection of patients for surgery. 
The detection of CLM has significantly
improved over the past decade, and
several different imaging techniques are
now available for follow-up of patients with
colorectal cancer. Generally, thin-cut
multiple-phase spiral computed tomog-
raphy (CT) is the preferred imaging
modality for detection of CLM because it is
the most widely available technique. It
allows study of the thorax, liver, abdomen,
and pelvis in the same examination, and
through the individual phases of the scan,
provides anatomic details of tumor and
vessel associations necessary for hepatic
resection planning. A comparable alternative
preferred by some centers is contrast-
enhanced magnetic resonance imaging
(MRI) using a combination of gadolinium
and superparamagnetic iron oxide.
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Resection of Colorectal Liver Metastases
Fluorodeoxyglucose positron emission
tomography (FDG-PET) appears to be a
useful tool for the detection of extrahepatic
disease5, however, its ability to assess the
liver itself is limited, as intrahepatic lesion
detection is poor, especially after chemo-
therapy.11 A recent meta-analysis provided
evidence that FDG-PET has higher sensi-
tivity in the detection of colorectal liver
metastases (94.6%) than does helical CT
(64.7%) or 1.5T MRI (75.8%).12 However,
the resolution of FDG-PET remains inferior
to that of CT or MRI, as does its specificity,
especially in patients who undergo pre-
operative chemotherapy. Finally, FDG-PET
does not provide anatomic details neces-
sary for surgical planning. Thus, the role of
FDG-PET in patients with CLM remains to
be determined.
Although some groups advocate
diagnostic laparoscopy to improve patient
selection for hepatic resection of CLM,13
improved preoperative imaging has limited
the role of laparoscopy in staging of this
disease. A more important application of
laparoscopy may be the evaluation of
underlying liver disease, such as cirrhosis,
steatosis, and chemotherapy-related liver
injuries, for which preoperative diagnosis
currently remains challenging.
In addition to careful assessment of
hepatic and extrahepatic involvement,
accurate measurement of liver volume is
mandatory when assessing patient candi-
dates for extensive hepatectomy to
determine the future liver remnant and the
need for preoperative portal vein emboliza-
tion.14 Volumetric data are obtained from
multiphase CT imaging used for staging
and surgical planning. The concept of liver
volumetry and its clinical significance are
discussed later in this paper.
DEFINITION OF RESECTABILITY  
The major oncologic contraindications to liver
surgery are the presence of unresectable
liver disease and the presence of extrahep-
atic disease (Table 1).
In the past, resection of CLM was not
performed in patients with more than three
metastases, an anticipated negative resection
margin of less than 1 cm, or extrahepatic
disease. However, recent studies have
shown that long-term survival is possible
even in patients with these clinicopatho-
logic factors, and as such, the definition of
resectability has shifted from one based on
tumor characteristics, such as tumor
number and size, to one based on whether
both intrahepatic and extrahepatic disease
can be completely resected (R0 resection).
An alternative interpretation is that there
has been a change from concentrating on
what is removed (tumor) to a focus on what
will remain after resection (liver remnant).
Currently, CLM should be considered
resectable when the patient has no under-
lying liver disease, and at least two
adjacent liver segments (representing not
less than 20% of the standardized future
liver remnant) can be spared with ade-
quate vascular inflow, outflow, and biliary
drainage.14,15 The following sections review
factors historically considered contraindi-
cations to hepatic resection for CLM and
data supporting or refuting these contraindi-
cations, including discussion of prognostic
factors vs. selection factors to define
resectability.
Number of Metastases
Multiple metastases and the presence of
bilobar disease are correlated with a less
favorable prognosis, especially in cases
where more than four metastatic sites are
involved, since these features are associ-
ated with higher risk of extrahepatic
disease and of systemic recurrence after
surgery. Indeed, such patients generally
undergo an extensive preoperative workup.
The application of FDG-PET may be partic-
ularly useful to detect extrahepatic disease
in such high-risk patients.5
Recently, Pawlik et al 6 reported on a
cohort of patients with more than four
metastases treated with multimodality 
therapy, including preoperative chemo-
therapy. The 5-year disease-free and over-
all survival rates were 22% and 51%,
respectively, after hepatic resection.
Similarly, Kokudo et al,16 in a review of
patients treated in Tokyo, found that a high
number of metas-
tases, although a
grim prognostic fac-
tor, should not be
considered a con-
traindication per se
to hepatic resection,
because surgery for
CLM is still the only
curative treatment.
Removal of up to
70% to 80% of the
liver parenchyma
can be accomplish-
ed safely, and the
mortality rate after
hepatic resection is
almost nil.17 There-
fore, the number of
metastases should no longer be considered
a contraindication for curative hepatic
resection but rather a prognostic factor,
which will be overcome by surgery and 
systemic chemotherapy in selected patients.
Surgical Margin
Historically, 1 cm was considered the
minimum safe surgical margin for hepatic
resection. Resections with an anticipated
Table 1. Contraindications to resection of colorectal liver metastases
Relative Absolute
Extrahepatic metastases Peritoneal carcinomatosis
Colonic recurrence Multiple extrahepatic metastases
Solitary resectable peritoneal metastasis Inability to perform hepatic R0 resection
Hilar lymph nodes metastases
Figure 1. Survival after curative resection for colorectal liver metastases, stratified
by margin status. No significant survival differences were seen in patients with
negative surgical margins, regardless of the width of the margin. Reprinted with
permission from Pawlik.7
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margin less than 1 cm were often defined
as “not radical,” and the scenario was
sometimes considered a contraindication
to resection. Studies of true margin recur-
rence have shown that a 1-cm margin is
not necessary to maximize survival proba-
bility. In a multicenter series of 557
patients reported by Pawlik et al, although
a positive surgical margin (R1) was associ-
ated with a modestly increased risk of local
tumor recurrence (11%), the width of the
resected margin did not predict increased
risk for margin recurrence or survival
(Figure 1).7 Similarly, other studies have
shown that nonanatomic resections, which
are usually associated with a minimal
margin, are not associated with an
increased risk of local recurrence after
surgery.18,19 These studies have clearly
shown that the anticipated minimal margin
should not be considered a contraindica-
tion for resection.
Hilar Lymph Node Metastases
Whether resection of CLM is indicated in
patients with hilar and perihepatic lymph
node metastases is an area of controversy.
Such lymph node metastases may predict
poor outcome after surgery for CLM. Jaeck
et al20 recently showed that hilar and
perihepatic lymph node metastases have a
stronger negative influence on prognosis
than do multiple and bilobar liver metas-
tases, elevation of carcinoembryonic
antigen level, or even the presence of a
solitary site of resectable peritoneal
disease. Therefore, the presence of hilar
lymph node metastases is generally
considered a contraindication to resection
of CLM and could be a good indicator of
the need for preoperative chemotherapy,
even in patients with resectable disease at
presentation. However, the precise role of
lymphadenectomy during surgery for CLM
has yet to be clarified.14
Extrahepatic Disease
Several authors have reported long-term
survival in patients with CLM and re-
sectable extrahepatic disease. Elias et al21
found a 28% 5-year overall survival rate in
patients with more than five metastases
and multiple extrahepatic disease sites
treated with radical surgery. Other studies
have shown that long-term survival can be
expected after complete resection of
pulmonary metastases from colorectal
cancer, even when such metastases are
detected at the same time as CLM. The
criteria to select patients for pulmonary
resection are currently under investigation.
It is generally accepted, however, that
patients can be considered for pulmonary
resection as long as it is technically
feasible and there is no evidence of 
hilar or paracardiac lymphadenopathy.
With strict selection
criteria, surgery for
CLM with extrahep-
atic sites can result
in survival rates of
78% at 3 years and
56% at 5 years.22
Molecular
Markers
The utility of clinico-
pathologic features
to predict prognosis
after complete resec-
tion of CLM is limited,
and molecular mark-
ers are sought to
improve prediction
of prognosis.
Specific molecular markers have been
linked with clinical outcomes. Human
telomerase reverse transcriptase (hTERT)
expression has been shown to be
independently associated with poor
prognosis after curative resection for CLM,
regardless of traditional clinicopathologic
predictors. In fact, patients with hTERT-
positive CLM have twice the risk of death
than patients without hTERT expression
(Figure 2). This important finding provides
evidence that molecular markers can
predict outcome after resection and may
be used to plan adjuvant therapy for high-
risk patients.23 More efforts are needed to
understand the potential roles of hTERT or
other markers and in which patients they
should be applied.
ADVANCES IN SURGICAL
TECHNIQUE
The current technique for liver resection is
based on liver segmental anatomy de-
scribed by Couinaud in 1957.24 Several
attempts have been made to elucidate the
significance of anatomic and nonanatomic
(limited) hepatic resections for CLM. A
recent systematic study that compared
outcomes after limited vs. anatomic resec-
tions for CLM showed no differences in
terms of tumor clearance, recurrence, or
long-term survival.25 In other words, ana-
tomic resections are not superior to limited
resections for CLM from an oncologic
standpoint. Thus, the principle that
outcome depends on complete resection
of metastatic disease applies whether
anatomic or nonanatomic resection (or a
combination) is used to extirpate disease.
This analysis corroborates the finding that
tumor biology, not resection type, predicts
prognosis.
Intraoperative Ultrasonography
Intraoperative ultrasonography (IOUS)
remains one of the most important tools in
liver surgery. Since its introduction more
than 20 years ago, IOUS has come into
widespread use by hepatobiliary surgeons.26
Several studies have shown that IOUS
complements the preoperative cross-
sectional imaging. In expert hands, IOUS
can reveal additional lesions in 10% to 15%
of patients, although improving preoper-
ative staging studies may reduce this aspect
of the IOUS advantage. More important,
IOUS is essential to define the parenchymal
transection plane and the relationship
between the tumor and the intrahepatic
vascular and biliary structures to assure
complete tumor resection and preservation of
critical vasculobiliary structures.27 The recent
introduction of contrast-enhanced IOUS may
further improve intraoperative staging.28
Figure 2. Negative effect of human telomerase reverse transcriptase (hTERT)
expression on overall survival in patients undergoing curative resection for
colorectal liver metastases. Patients with nucleolar hTERT staining had signifi-
cantly shortened survival. Reprinted with permission from Dômont et al.23
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Hemorrhage Control
One of the most powerful, independent deter-
minants of outcome after hepatic resection
is the amount of intraoperative blood loss.29,30
Maintenance of low central venous
pressure, usually less than 5 mm Hg, has
been shown to reduce blood loss from
hepatic veins and hepatic parenchyma during
liver transection.31,32 Different clamping
methods to reduce intraoperative hemor-
rhage have also been developed, such 
as continuous or intermittent pedicle
clamping (Pringle’s maneuver), clamping
of hemi-liver, and total vascular exclusion
of the liver with or without clamping of the
inferior vena cava.33 In general, most
elective resections can be performed
safely with intermittent pedicle clamping;
use of total vascular exclusion techniques
is rarely necessary34–36 and is usually
associated with hemodynamic changes
and the consequent increases in postoper-
ative morbidity and mortality rates.
Recently developed devices including
radiofrequency coagulators, saline-linked
cautery, and ultrasonic dissectors allow
hemostatic parenchymal transection with
minimal blood loss.37 However, a prospec-
tive randomized trial found no significant
differences in blood loss when surgery was
performed using such new transection
devices and the traditional crush technique.38
The contribution of postoperative pain
control is also worthy of note. Use of
continual epidural analgesia provides
optimal pain control, allowing improved
respiratory function (which was previously
a problem in patients with upper abdominal
incisions) and early patient mobilization,
thus significantly reducing morbidity rates.
SHORT-TERM AND LONG-TERM
RESULTS OF RESECTION
Liver resection is a well-established proce-
dure, with a mortality rate of less than 5%
and morbidity rates of less than 30% to
40%. Important determinants of poor
outcome after liver resection are intraoper-
ative bleeding, perioperative blood
transfusions, insufficient remnant liver,
and development of infective complica-
tions. These conditions can lead to hepatic
failure, which, although it occurs in fewer
than 4% of cases, can be devastating.
Proper patient selection, meticulous 
intraoperative technique, and careful post-
operative management are essential to
minimize surgical complications.
Table 2 reports long-term results from
major published series of liver resection for
CLM and includes the main predictors of
recurrence.5,7–9,19,39–48 Despite expanding
indications for resection of CLM, 5-year
overall survival is now consistently reported
as 51% to 58% in single- and multi-institu-
tional studies.5–10 Of note, recent studies
included patients with advanced multiple
and bilateral disease, who were not consid-
ered for resection until a few years ago, and
patients treated with preoperative systemic
chemotherapy, which has a definite role in
achieving long-term survival. 
The main clinicopathologic factors that
are useful to predict prognosis after
hepatic resection for CLM are margin
status, stage of the primary colon tumor,
preoperative carcinoembryonic antigen
level, size and number of lesions, and
presence or absence of extrahepatic
metastases. These prognostic factors were
determined before the advent of effective
systemic chemotherapy, however, so their
utility as prognostic indicators in this new
era of CLM management is unknown. With
advances in molecular techniques, bio-
logic factors such as hTERT are emerging
as potential prognostic indicators and may
prove more accurate than clinical factors.23
STRATEGIES TO IMPROVE
RATES OF RESECTABILITY 
Progress in systemic chemotherapy com-
binations, in conjunction with advances in
surgical technique and patient selection,
has significantly expanded the population
of patients for whom potentially curative
Table 2. Predictors of recurrence and long-term survival after resection for colorectal liver metastases
R1 Synchronous Primary Size of No. Preoperative Extrahepatic 5-Year 
Author, Year Status Presentation Nodes + Metastases Metastases CEA Disease Survival
Fernandez, 20045 – – – + – 58%
Pawlik, 20057 + – – + + + 58%
Abdalla, 20048 + – + + 58%
Choti, 20029 + – – – + + 58%
Elias, 199819 + + – – – – – 28%
Gayowski, 199439 + + + – + – + 32%
Scheele, 199540 + + + + – – – 40%
Nordlinger, 199641 + + + + + + 28%
Jaeck, 199742 + + + + + + – 26%
Jamison, 199743 – – – 32%
Jenkins, 199744 + – – + 25%
Ambiru, 199945 + – + + + 23%
Fong, 199946 + + + + + 46%
Minagawa, 200047 – – – + – – 38%
Figueras, 200148 + – + + + 53%
CEA, Carcinoembryonic antigen.
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hepatic resection of CLM is possible.
Examples of relatively new techniques
include preoperative chemotherapy, portal
vein embolization, two-stage hepatectomy
for bilateral liver metastases, extended
hepatectomy, and repeat hepatectomy.
Many patients who would not have been
considered for resection just a few years
ago are now treated with preoperative,
cytoreductive chemotherapy followed by
liver surgery. 
Preoperative Systemic
Chemotherapy
The development of new, more effective
chemotherapy agents has led to a signifi-
cant survival increase for patients with
unresectable stage IV colon cancer.
Oxaliplatin and irinotecan, agents that are
commonly used in conjunction with 5-
fluorouracil/folinic acid–based therapies,
can downsize liver metastases and control
potential sites of extrahepatic disease49 to
permit subsequent resection of residual
disease.
The indications for preoperative sys-
temic chemotherapy are generally based
on risk factors for disease recurrence,
such as tumor size, tumor number,
disease-free interval, and presence or
absence of extrahepatic disease.
The increased use of preoperative
chemotherapy poses a clinical dilemma;
whether to prescribe or not to prescribe
preoperative chemotherapy in patients
with initially resectable disease. This
dilemma is not merely academic, because
recent reports indicate an increased risk of
adverse post-resection events in patients
treated with preoperative systemic chemo-
therapy. Liver injury, such as hepatic
steatosis and steatohepatitis, has been
described in irinotecan-treated patients,
and intravascular damage, such as
sinusoidal obstruction, has been reported
in oxaliplatin-treated patients.50,51 These
chemotherapy-related liver injuries may
reduce the regenerative capacity of
hepatocytes in response to major hepatec-
tomy through alterations of nuclear factors,
such as the nuclear factor-kappa B (NF-
κB), which is crucial for the priming phase
of liver regeneration, and increase postop-
erative morbidity and even mortality. 
Although resection has been shown to
be safe after preoperative chemotherapy,52,53
mortality is increased in certain types of
chemotherapy-related hepatic injuries—
specifically, steatohepatitis in association
with irinotecan therapy.54 Thus, use of
preoperative chemotherapy should be
carefully considered in patients with
resectable disease at presentation; devel-
opment of intrahepatic complications
could necessitate modification of the
surgical strategy or even rule out surgery
altogether as a treatment option. In light of
this clinical dilemma, molecular markers
are needed to help predict which patients
are most likely to respond to preoperative
chemotherapy and which drugs or drug
classes will be more effective and better
tolerated by a given patient. 
Portal Vein Embolization
Portal vein embolization (PVE) in prepara-
tion for major hepatic resection has been
shown to induce hypertrophy of the future
liver remnant and reduce risk of postoper-
ative liver failure after major hepatectomy.55
First described by the Japanese for
patients with primary liver cancer, PVE has
become part of clinical practice and con-
tributes to improvements in resectability
rates of liver cancer.56,57
PVE is usually performed through a
percutaneous transhepatic ipsilateral
approach, which uses ultrasound-guided
puncture of a portal branch followed by
embolization of the entire lobar portal terri-
tory to be resected. A variety of substances
have been used for embolization, including
absolute alcohol, ethiodized oil, and
cyanoacrylate, none of which has been
shown superior to another.58 PVE is a well-
established and well-tolerated procedure.
In our series of 112 cases, the complica-
tion rate is 8.9%, and includes hematoma,
partial portal vein thrombosis, esophageal
hemorrhage, and migration of embolizing
material. Only one patient was deemed
unresectable as a result of a PVE-related
complication, but he also had tumor
progression, which presented a contraindi-
cation to resection (The University of Texas
M. D. Anderson Cancer Center, unpub-
lished data, 11/2/2006).
Indications for PVE are based on the
standardized future liver remnant volume
(sFLR) and the presence or absence of
underlying liver disease. The sFLR is
calculated using the ratio between FLR
and total liver volume (TLV). The FLR is
directly measured with CT volumetry of the
liver, and TLV is calculated using a formula
derived from the association between TLV
and body surface area, which estimates
the hepatic metabolic demand for each
patient.59 The presence of underlying liver
disease is important because severely
damaged livers may not have the capacity
to regenerate. Both cirrhosis and severe
steatosis have been found to impair liver
regeneration significantly after major
hepatectomy. Use of PVE in these settings
will allow hypertrophy of the non-tumor–
bearing liver, albeit at a slower rate than for
healthy liver, thus reducing the risk of
subsequent hepatectomy.
Hypertrophy of the remnant liver
follows a nonlinear kinetic profile during
the first 2 months after PVE. The greatest
increase in liver volume (75%) occurs
within 3 weeks after PVE, after which a
plateau phase of minimal regeneration is
reached (The University of Texas M. D.
Anderson Cancer Center, unpublished
data, 11/2/2006). This is in agreement
with recent data showing that hypertrophy
of the nonembolized liver is regulated
mainly by transforming growth factor-alpha
(TGF-∝),
60 the serum level of which peaks
within 20 days after PVE and then reaches
a plateau.61
It has recently been shown that hyper-
trophy of the remnant liver following PVE
occurs through two complementary
mechanisms—namely, increased prolifer-
ation and hypertrophy of hepatocytes in
the remnant liver.62 Thus, the optimum
interval of time to assess hypertrophic
response to PVE is 3 to 4 weeks. At this
time, repeat CT volumetry can provide two
crucial pieces of information: (1) whether an
adequate liver volume has been reached;
and (2) rate of growth, which is indicative
of the regenerative reserve of the liver. We
found that patients with slow liver growth
during the first month had a significantly
worse clinical outcome, regardless of
whether the target sFLR was reached.
The liver volume limit for safe resection
varies from patient to patient. In patients
with an otherwise normal liver, PVE is
indicated when the sFLR is <20%. In our
experience, an sFLR less than 20% is
associated with a significant increase in
postoperative morbidity (Figure 3). In
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patients who have received extensive
preoperative chemotherapy or with exten-
sive steatosis, which can affect liver
regeneration, a larger liver volume cut-off
of <30% has been proposed. Finally,
among patients with underlying cirrhosis,
PVE is indicated when sFLR is <40%.14
Contraindications to PVE include tumor
invasion of the portal vein, portal throm-
bosis, uncorrectable coagulopathy, biliary
dilation in the FLR, severe portal hyperten-
sion, and renal failure.
Two-Stage Hepatectomy
The resection of multiple bilobar CLM can
cause an excessive reduction of the FLR,
which may in turn lead to postoperative liver
failure. In 2000, Adam et al63 proposed a
novel two-stage approach for initially unre-
sectable liver tumors. The highest possible
number of tumors is removed in the first
operation, and a second operation is per-
formed after a period of liver regeneration
to remove the remaining tumors. The
rationale for two-stage hepatectomy is to
minimize the risk of liver failure associated
with massive hepatectomy in patients with
bilateral metastases. 
At our institution, we have inverted the
sequence to perform minor resections as
the first stage, usually in the future
remnant liver, and later major or extended
resections as the second stage with or
without PVE, according to the FLR volume.
This approach allows us to perform
additional major procedures, such as
resection of the primary tumor, at the first
stage with low morbidity, as well as subse-
quent major resection. The need for
interim chemotherapy or PVE can there-
fore be assessed before the subsequent
major resection. This approach has been
validated by Jaeck et al,64 who recently
proposed a systematic approach based on
the two-stage hepatectomy with or without
preoperative PVE to permit curative resec-
tion for CLM. They reported 1- and 3-year
overall survival rates of 70% and 54.4%,
respectively.
The two-stage strategy should be con-
sidered in patients not eligible to undergo
R0 resection in one procedure. However,
selection criteria and use of preoperative
chemotherapy in patients with multiple
and bilobar CLM remain to be clarified.
Repeat Hepatectomy
Most patients who undergo hepatic resec-
tion for CLM develop disease recurrence,
and one third of those develop isolated
intrahepatic recurrence. Selected patients
with isolated hepatic recurrence can
undergo repeat hepatectomy and attain
long-term survival. After third hepatec-
tomy, a 5-year overall survival rate of 32%
can be expected, and postoperative mor-
bidity and mortality rates are no higher
than after first hepatectomy.65 As multiple
bilobar CLM are associated with high rates
of hepatic recurrence, early diagnosis of
recurrent disease is essential to maximize
the number of patients eligible for repeat
resection, because long-term survival can
be achieved with this approach.
Radiofrequency Ablation
Unfortunately, not all patients are can-
didates for hepatic resection for CLM and
alternative therapies have therefore been
proposed. The most
common alternative
therapy used to
treat CLM is radio-
frequency ablation
(RFA). RFA consists
of placement of an
electrode within the
liver tumor under
radiologic guidance
(ultrasound [US], CT,
or MRI) that gene-
rates thermal (radio-
frequency)  energy to
destroy the tumor and
a margin of normal
parenchyma. RFA
can be performed
percutaneously, lap-
aroscopically, or dur-
ing laparotomy.
Use of RFA for
liver metastases has
been reported to be
effective and safe
by many authors.
Larger follow-up data
confirm the proce-
dure’s safety, but
suggest that RFA
may not be equiva-
lent to resection as
a local modality.
Abdalla et al 8 com-
pared results using
surgical resection
vs. RFA vs. a com-
bined procedure (resection plus ablation)
for CLM, and found a higher 5-year recur-
rence rate after RFA than after the
combined procedure or resection only
(84%, 64%, and 52%, respectively). Liver-
only recurrence following RFA was four
times that of resection, as was true local
recurrence. Consequently, long-term sur-
vival was better after resection than after
local ablation (65% vs. 22%) (Figure 4).8
The same group subsequently studied
solitary CLM and showed that hepatic re-
section is associated with superior survival
rates.66 The local recurrence rate was sig-
Figure 3. Complications rate stratified by standardized future liver remnant
(sFLR) volume. Patients with sFLR less than 20% had significantly more compli-
cations than patients with sFLR greater than 20% (The University of Texas M. D.
Anderson Cancer Center, unpublished data, 11/2/2006).
Figure 4. Overall survival of patients with colorectal liver metastases stratified by
type of treatment. Long-term survival was significantly higher in resected
patients. Reprinted with permission from Abdalla et al.8
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nificantly lower after resection (5%) than
after RFA (37%) for solitary CLM, and 5-year
overall survival rate was markedly longer
after resection (71%) than after RFA (27%).
In a large study reported by de Baere et
al, procedure-related mortality associated
with RFA was approximately 2%.67 Some
authors have reported altered growth
patterns of recurrent disease after RFA,
including sarcomatous and disseminated
spreading patterns.68 If such recurrences
are amenable to resection, a more aggres-
sive approach is usually needed, which
increases postoperative morbidity and
mortality.
Based on experience to date with RFA,
surgical resection should be considered
the treatment of choice for CLM, with RFA
restricted to patients who are not candi-
dates for resection because of general
contraindications, severe underlying liver
disease that could impair postsurgical
recovery, or technically unresectable
disease. Therefore, because of inferior
results with RFA and the availability of
multiple resection modalities, patients
should always be referred to surgeons with
hepatobiliary expertise to determine their
eligibility for resection before RFA is
considered.
CONCLUSIONS
Hepatobiliary surgeons and medical oncol-
ogists should work together to evaluate
patients with CLM to individualize treat-
ment strategies and maximize the chances
of long-term survival. Today, through a multi-
disciplinary and multimodality approach,
and use of a wide variety of available
techniques, it is possible to manage CLM
successfully and offer many patients long-
term survival. 
Increasing acceptance of the role of
liver resection in the management of CLM
by the medical community as well as the
public will no doubt lead to development of
standardized population-wide screening
protocols for patients undergoing colonic
resection, similar to those currently used in
specialized units. Improved screening and
earlier identification of CLM will lead to
increasing resectability rates and improved
outcomes for more patients.  
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